Business · Markets · StrategySupport
CII — Corporate Insider Inc.CII
Subscribe
S&P 5006,412.08+0.62%
NASDAQ21,884.30+1.04%
DOW44,910.55-0.18%
10-YR4.13%-0.03
BRENT$71.44+0.91%
BTC$96,120-2.11%
S&P 5006,412.08+0.62%
NASDAQ21,884.30+1.04%
DOW44,910.55-0.18%
10-YR4.13%-0.03
BRENT$71.44+0.91%
BTC$96,120-2.11%

Strategy

Zymeworks Raises 2026 Guidance and Details Final Terms of Its $17-a-Share Theravance Biopharma Acquisition

The biotech funded the deal with a $350 million non-recourse note and cash, and is shifting to adjusted EBITDA as a headline metric.

AF

By Anna Ferreira

Sep 29, 2026 · 5 min read

Zymeworks (Nasdaq: ZYME) said Monday it had updated its 2026 financial guidance and disclosed the final terms of its acquisition of Theravance Biopharma, a transaction that closed Sept. 23.

Discussion (0)

Sign in to join the discussion.

Loading comments…

AF

Anna Ferreira

Senior Correspondent, Corporate Strategy

Anna Ferreira writes for Corporate Insider Inc.

CII Briefing

The 7am memo for people who run things

One email. The deals, the numbers and the decisions that will be discussed in your Monday meeting.

Free. Unsubscribe any time. We never share your address.